Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    When the Provider Becomes the Patient: What I Learned From COVID-19
    COVID-19
    When the Provider Becomes the Patient: What I Learned From COVID-19
    June 24, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice
    The Case of the Late Head and Neck Lymphedema
    June 20, 2022
    Our Patients Give Us Peace in Unexpected Circumstances
    Oncology nurse pride
    Our Patients Give Us Peace in Unexpected Circumstances
    June 17, 2022
    Behind Our Masks, I See You, I Hear You
    COVID-19
    Behind Our Masks, I See You, I Hear You
    June 10, 2022
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    Oncology nurse-patient relationship
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    June 03, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Patient safety

    FDA Reports BD’s Recall of Intraosseous Products
    U.S. Food and Drug Administration (FDA)

    FDA Reports BD’s Recall of Intraosseous Products

    On June 22, 2022, the U.S. Food and Drug Administration (FDA) reported Becton, Dickinson and Company’s (BD’s) voluntary recall of its intraosseous needle set kits, manual driver kits, and powered drivers. Use of the products could lead to needlestick injuries or delays in care because of limited or non-functioning intraosseous access.

    June 27, 2022
    FDA Reports Recall of CVS Magnesium Citrate Saline Laxative Oral Solution Lemon Flavor Due to Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of CVS Magnesium Citrate Saline Laxative Oral Solution Lemon Flavor Due to Microbial Contamination

    On June 21, 2022, the U.S. Food and Drug Administration (FDA) reported Vi-Jon, LLC’s, voluntarily recall of one lot of CVS magnesium citrate saline laxative oral solution lemon flavor, 10 fl oz (296 ml), after testing revealed the product contains the bacteria Gluconacetobacter liquefaciens.

    June 27, 2022
    FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of Milk of Magnesia Oral Suspension and Magnesium Hydroxide/Aluminum Hydroxide/Simethicone Oral Suspension

    On June 8, 2022, the U.S. Food and Drug Administration (FDA) reported Plastikon Healthcare's voluntarily recall of one lot of Milk of Magnesia 2,400 mg/10 ml oral suspension, one lot of Milk of Magnesia 2,400 mg/30 ml oral suspension, 11 lots of magnesium hydroxide 1,200 mg/aluminum hydroxide 1,200 mg/simethicone 120 mg per 30 ml oral suspension, and two lots of magnesium hydroxide 2,400 mg/aluminum hydroxide 2,400 mg/simethicone 240 mg per 30 ml oral suspension to the consumer level because of microbial contamination.

    June 10, 2022
    FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks
    U.S. Food and Drug Administration (FDA)

    FDA Reports Illumina Cybersecurity Vulnerability May Present Risks for Patient Results and Customer Networks

    On June 2, 2022, the U.S. Food and Drug Administration (FDA) reported a cybersecurity vulnerability that affects software in the Illumina NextSeq 550Dx, MiSeqDx, NextSeq 500, NextSeq 550, MiSeq, iSeq, and MiniSeq next generation sequencing instruments. The devices are used in diagnostic (Dx), research-use only (RUO), or dual boot (either Dx or RUO) modes. 

    June 03, 2022
    COVID-19 Contributes to Climbing Costs of Cancer Care
    COVID-19

    COVID-19 Contributes to Climbing Costs of Cancer Care

    Cancer is one of the top five most expensive healthcare conditions to treat, costing the United States more than $157 billion annually. The payout from patients’ pockets may be even greater, with the cost of cancer medications alone standing at $895 billion per year. But paying for cancer during a pandemic? Even financially secure patients with healthcare coverage are struggling.

    April 21, 2022
    FDA Reports Safety Announcement for Spectrum V8 and Spectrum IQ Infusion Pumps
    U.S. Food and Drug Administration (FDA)

    FDA Reports Safety Announcement for Spectrum V8 and Spectrum IQ Infusion Pumps

    On February 18, 2022, the U.S. Food and Drug Administration (FDA) reported Baxter International’s urgent safety communication to reinforce safety information regarding upstream occlusion alarms for all Spectrum V8 and Spectrum IQ infusion pumps.

    February 24, 2022
    E-Cigarettes Affect Adults and Kids Differently, FDA Center for Tobacco Products Director Says
    Patient safety

    E-Cigarettes Affect Adults and Kids Differently, FDA Center for Tobacco Products Director Says

    Balancing the benefits of e-cigarettes for adults with the harms makes regulating e-cigarette marketing particularly challenging, U.S. Food and Drug Administration (FDA) Center for Tobacco Products Director Mitch Zeller, JD, said in a January 2022 interview with the National Cancer Institute (NCI). FDA continuously evaluates e-cigarettes and tobacco companies’ marketing strategies, and Zeller says it’s up to tobacco companies to make those differences clear in their advertising.

    February 23, 2022
    FDA Reports Nationwide Recall of Senna Syrup 8.8 mg/5 ml Because of Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    FDA Reports Nationwide Recall of Senna Syrup 8.8 mg/5 ml Because of Microbial Contamination

    On January 12, 2022, the U.S. Food and Drug Administration (FDA) reported Lohxa’s voluntary recall of one lot of senna syrup 8.8 mg/5 ml unit-dose cups to the consumer level because of microbial contamination.

    January 13, 2022
    Make Subcutaneous Administration More Comfortable for Your Patients
    Clinical practice

    Make Subcutaneous Administration More Comfortable for Your Patients

    Much of oncology nursing education focuses on IV administration of systemic therapies because for years, that was the only route. Until 2004, only two cancer therapies were approved for subcutaneous (SC) administration, and just nine others were added through 2012. However, as more familiar IV therapies get SC counterparts, including the more recent approvals of four high-volume monoclonal antibodies (mAbs), infusion nurses are using them more regularly in practice.

    January 04, 2022
    HHS Secretary Becerra Announces New Overdose Prevention Strategy
    Health Policy

    HHS Secretary Becerra Announces New Overdose Prevention Strategy

    Preventing overdoses—from any substance, but particularly opioids—is an urgent need during the U.S. opioid epidemic that involves a four-step process: prevention, harm reduction, treatment, and recovery, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra announced. HHS released a new overdose prevention strategy in October 2021 to increase access to services for patients and their families who use substances that can put them at risk for overdose.

    December 16, 2021
    Black Patients at Higher Risk for Infection, Poor Outcomes From COVID-19 During Cancer
    COVID-19

    Black Patients at Higher Risk for Infection, Poor Outcomes From COVID-19 During Cancer

    Patients with cancer are more likely to contract the COVID-19 coronavirus and experience complications from the infection—and the risk is highest for Black patients, study findings show. Researchers published the report in JAMA Oncology.

    December 15, 2021
    FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%
    U.S. Food and Drug Administration (FDA)

    FDA Reports Teligent Pharma’s Worldwide Voluntary Recall of Lidocaine HCl Topical Solution 4%

    On December 7, 2021, the U.S. Food and Drug Administration (FDA) reported Teligent Pharma’s voluntary recall of two lots of lidocaine HCl topical solution 4% in a 50 ml screw cap glass bottle to the user level. The manufacturer’s testing found that the product is super potent based on an out-of-specification result at the 9-month (lot 16345) and 18-month (lot 15594) stability timepoint.

    December 08, 2021
    FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind
    U.S. Food and Drug Administration (FDA)

    FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind

    Under the authority given in the Family Smoking Prevention and Tobacco Control Act, in October 2021 the U.S. Food and Drug Administration (FDA) authorized the marketing of three new electronic nicotine delivery system (ENDS) products, “marking the first set of ENDS products ever to be authorized by FDA through the Premarket Tobacco Product Application pathway.” The agency made the announcement it continues its review of thousands of tobacco and e-cigarette products’ marketing applications.

    November 17, 2021
    FDA Reports Recall of Custom Convenience Kits Because of Prefilled Syringe Plunger Defect
    U.S. Food and Drug Administration (FDA)

    FDA Reports Recall of Custom Convenience Kits Because of Prefilled Syringe Plunger Defect

    On November 9, 2021, the U.S. Food and Drug Administration (FDA) reported Aligned Medical Solutions’ recall of its custom convenience kits because of the potential for the plunger of the Cardinal Health monoject flush prefilled syringe (0.9% sodium chloride) to draw back after the air has been expelled and reintroduce air back into the syringe. FDA identified the recall as a class I recall, the most serious type of recall.

    November 12, 2021
    Many Popular Online Cancer Articles Contain Misleading Information, NCI Says
    Patient Education

    Many Popular Online Cancer Articles Contain Misleading Information, NCI Says

    With a plethora of information available online, patients with cancer and their families have access to plenty of resources to learn more about their diagnosis and treatment options. However, one-third of the online articles about cancer circulating on social media contain incorrect information, according to findings from a 2021 study published in the Journal of the National Cancer Institute.

    October 29, 2021
    FDA Amends EUAs With Booster Doses for COVID-19 Vaccines
    COVID-19

    FDA Amends EUAs With Booster Doses for COVID-19 Vaccines

    On October 20, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) for the Moderna and Janssen (Johnson and Johnson) COVID-19 vaccines to allow for the use of a single booster dose for certain populations.

    October 22, 2021
    FDA Reports Worldwide Recall of Lidocaine HCl Topical Solution 4% Because of Super Potency
    U.S. Food and Drug Administration (FDA)

    FDA Reports Worldwide Recall of Lidocaine HCl Topical Solution 4% Because of Super Potency

    On October 13, 2021, the U.S. Food and Drug Administration (FDA) reported Teligent Pharma’s voluntary recall of five lots of lidocaine HCl topical solution 4% in a 50 ml screw cap glass bottle to the user level because the firm’s testing found it to be super potent based on an out-of-specification result obtained at the 18-month stability timepoint.

    October 14, 2021
    FDA Issues Marketing Denial Orders for 55,000 Flavored E-Cigarette Products
    U.S. Food and Drug Administration (FDA)

    FDA Issues Marketing Denial Orders for 55,000 Flavored E-Cigarette Products

    In August 2021, the U.S. Food and Drug Administration (FDA) denied about 55,000 flavored e-cigarette products’ marketing applications for failing to provide evidence that they appropriately protect public health.

    October 01, 2021
    IntegraDose Compounding Services Issues Voluntary Nationwide Recall of Cefazolin Injection Products Because of a Lack of Sterility Assurance
    U.S. Food and Drug Administration (FDA)

    IntegraDose Compounding Services Issues Voluntary Nationwide Recall of Cefazolin Injection Products Because of a Lack of Sterility Assurance

    On September 21, 2021, the U.S. Food and Drug Administration (FDA) reported IntegraDose Compounding Services’ voluntary recall of nine lots of cefazolin 2 g in 20 ml syringe for injection and two lots of cefazolin 3 g in 100 ml 0.9% sodium chloride bag for injection because of a lack of sterility assurance resulting from compounding in a newly installed biologic safety cabinet without completing dynamic smoke study testing.

    September 27, 2021
    Pfizer Expands Recall to Include All Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    Pfizer Expands Recall to Include All Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On September 17, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of all lots of varenicline 0.5 mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, at or above the FDA interim acceptable intake limit. FDA said that while Pfizer is undertaking the precautionary measure, alternative suppliers have been approved in the United States.

    September 20, 2021
    FDA Reprimands Tobacco Company for Not Meeting Premarketing Filing Requirements
    U.S. Food and Drug Administration (FDA)

    FDA Reprimands Tobacco Company for Not Meeting Premarketing Filing Requirements

    On August 9, 2021, the U.S. Food and Drug Administration issued a refuse-to-file letter (RTF) to JD Nova Group, notifying the company that their premarket tobacco product applications associated with approximately 4.5 million of their products do not meet the filing requirements for a new tobacco product seeking a marketing order.

    September 16, 2021
    The Case of the Swift Sepsis Response
    Oncologic emergencies

    The Case of the Swift Sepsis Response

    Simon is a 72-year-old patient diagnosed with myelodysplastic syndrome and acute myeloid leukemia. He underwent an HLA-identical sibling peripheral blood stem cell transplantation with fludarabine and melphalan as conditioning chemotherapies before the procedure. Simon is now more than 12 days posttransplant but still neutropenic with an absolute neutrophil count of 0. He has no signs of engraftment, is on total parenteral nutrition, and requires multiple blood transfusions and electrolytes through his central line catheter daily.

    September 03, 2021
    FDA Approves Zanubrutinib for Waldenström Macroglobulinemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Zanubrutinib for Waldenström Macroglobulinemia

    On August 31, 2021, the U.S. Food and Drug Administration (FDA) approved zanubrutinib (Brukinsa®) for adult patients with Waldenström macroglobulinemia (WM).

    September 02, 2021
    FDA Grants Full Approval for First COVID-19 Vaccine
    U.S. Food and Drug Administration (FDA)

    FDA Grants Full Approval for First COVID-19 Vaccine

    On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine, now marketed as Comirnaty, for the prevention of COVID-19 coronavirus infection in individuals aged 16 years and older. The vaccine is still under emergency use authorization (EUA) for individuals aged 12–15 years and as a third dose in certain immunocompromised individuals.

    August 25, 2021
    FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma

    On August 19, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk for recurrence after undergoing radical resection.

    August 23, 2021
    FDA Expands Recall to Include Four Additional Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    FDA Expands Recall to Include Four Additional Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On August 16, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of an additional four lots of varenicline 0.5mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, above the Pfizer-established acceptable daily intake level. To date, Pfizer has not received any reports of adverse events that have been related to the recall. FDA reported Pfizer’s recall of 12 lots of varenicline tablets because of N-nitroso varenicline content on July 19, 2021.

    August 19, 2021
    Overall Youth Tobacco Use Declines, but E-Cigarette Use Climbs, According to National Survey Results
    Lung Cancer

    Overall Youth Tobacco Use Declines, but E-Cigarette Use Climbs, According to National Survey Results

    American youth reported a decline in using any tobacco product in 2020 compared to 2019 but no significant decrease in the use of cigarettes, hookah, pipe tobacco, or heated tobacco products, according to 2020 U.S. Food and Drug Administration (FDA) survey findings on youth tobacco use. Despite the decline, FDA said that the data shows “disturbingly high rates of frequent and daily e-cigarette use” and strong nicotine dependence among youth.

    August 16, 2021
    Baxter Healthcare Recalls Dose IQ Software Version 9.0.x Because of Software Defect
    U.S. Food and Drug Administration (FDA)

    Baxter Healthcare Recalls Dose IQ Software Version 9.0.x Because of Software Defect

    On August 12, 2021, the U.S Food and Drug Administration (FDA) reported Baxter Healthcare’s recall of the Dose IQ Safety Software used with the Spectrum IQ Infusion System because a software defect may lead to mismatched drug information in drug libraries that were created using version 9.0.x of the computer-based software. FDA identified it as a class I recall, the most serious type of recall, where use of the devices may cause serious injuries or death.

    August 13, 2021
    FDA Announces Recall for SterRX, LLC, Sodium Bicarbonate in 5% Dextrose Injection Because of Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall for SterRX, LLC, Sodium Bicarbonate in 5% Dextrose Injection Because of Microbial Contamination

    On August 10, 2021, the U.S. Food and Drug Administration (FDA) reported SterRx, LLC’s, voluntary recall of three lots of sodium bicarbonate in 5% dextrose injection 150 mEq per 1,000 ml due to waterborne microbial contamination.

    August 12, 2021
    Nursing Informaticists Are the Backbone of Technology-Driven Care
    Oncology nursing roles

    Nursing Informaticists Are the Backbone of Technology-Driven Care

    Emerging healthcare technologies require a significant investment in time, money, and training. It starts with ensuring that quality improvement efforts are consistent to support positive clinical and patient outcomes, which is why clinical and information technology (IT) representation is critical in making decisions and exploring solutions. Nursing informatics bridges that gap.

    August 03, 2021
    FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall for 12 Lots of Varenicline Tablets Because of N-Nitroso Varenicline Content

    On July 19, 2021, the U.S. Food and Drug Administration (FDA) reported Pfizer’s voluntary recall of two lots of varenicline 0.5 mg tablets, two lots of varenicline 1 mg tablets, and eight lots of a varenicline kit of 9.5 mg/1 mg tablets to the patient level because of the presence of N-nitroso-varenicline, a nitrosamine, above the Pfizer-established acceptable daily intake level. Varenicline is a treatment to help patients quit smoking and is intended for short-term use. To date, Pfizer has not received any reports of adverse events that have been related to the recall.

    July 22, 2021
    FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter
    U.S. Food and Drug Administration (FDA)

    FDA Announces Recall of One Lot of Topotecan Injection Because of Presence of Particulate Matter

    On July 1, 2021, the U.S. Food and Drug Administration (FDA) reported Teva Pharmaceuticals’ June 30, 2021, voluntary recall of lot 31328962B of topotecan injection 4 mg/4 ml. The recall was based on a report that a single vial contained a glass particle, a grey silicone particle, and a translucent, colorless cotton fiber.

    July 22, 2021
    Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation
    Treatment side effects

    Oncology Dietitians Tackle Nutritional Barriers and Dispel Misinformation

    Because they often face nutrition challenges—such as nausea, taste alterations, difficulty swallowing, and altered gastrointestinal function—that develop during their journey and hinder their nutrition stability, patients with cancer have increased nutrient needs. Oncology dietitians are experts at guiding patients and caregivers through the nutritional process and developing solutions.

    July 06, 2021
    Food for Thought: Prevent and Screen for Malnutrition in Patients with Cancer
    Clinical practice

    Food for Thought: Prevent and Screen for Malnutrition in Patients With Cancer

    Malnutrition affects 30%–85% of all patients with cancer, making it one of the most common symptoms for oncology nurses to manage. To help patients achieve the best outcomes, clinicians must understand how and when to screen for malnutrition and how nutritional status affects treatment outcomes and patients’ quality of life.

    July 06, 2021
    FDA Announces Recall of BD Alaris Pump Module Model 8100 Because of Risk of Stuck or Unresponsive Keys
    U.S. Food and Drug Administration (FDA)

    FDA Announces Several New Recalls of BD Alaris Pump Module Model 8100 Because of Key and Bezel Problems

    On April 16, 2021, the U.S. Food and Drug Administration (FDA) reported Care Fusion 303, Inc.’s, recall of the BD Alaris Pump Module 8100 because the device may experience stuck or unresponsive keys during operation. FDA identified it as a class I recall, the most serious type of recall, where use of the devices may cause serious injuries or death.

    April 22, 2021
    FDA Makes Strides in Premarket Review of Tobacco Product Applications
    U.S. Food and Drug Administration (FDA)

    FDA Makes Strides in Premarket Review of Tobacco Product Applications

    The U.S. Food and Drug Administration’s (FDA’s) Center for Tobacco Products has aggressively fought to obtain tighter tobacco product regulations to protect adolescent lungs. One of those ways is through premarket review, where e-cigarettes and other new tobacco products that were available as of August 8, 2016, were required to submitted applications to FDA for approval by Sept. 9, 2020.

    April 20, 2021
    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection
    Clinical practice

    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection

    On March 25, 2021, the U.S. Food and Drug Administration shared Zydus Pharmaceuticals Inc.’s notice of its voluntary recall of four lots of acyclovir sodium injection 50 mg/ml, supplied in 10 ml and 20 ml vials, after receiving reports of crystallization in the product.

    March 29, 2021
    Infection Prevention for Oncology Nurses
    Clinical practice

    Infection Prevention for Oncology Nurses

    Regardless of care setting, oncology nurses must be vigilant about creating a safe environment for and educating patients about the importance of infection prevention. Patients with cancer are at increased risk for viral, bacterial, and fungal infections, but the extent depends on cancer type and treatment. 

    March 25, 2021
    FDA Advises Healthcare Professionals Not to Use BD’s ChloraPrep™ 3 ml Applicators
    U.S. Food and Drug Administration (FDA)

    FDA Advises Healthcare Professionals Not to Use BD’s ChloraPrep™ 3 ml Applicators

    On March 19, 2021, the U.S. Food and Drug Administration (FDA) issued an advisory to healthcare professionals not to use ChloraPrep 3 ml applicators manufactured by BD (Becton, Dickinson and Company) because of the risk of microbial contamination. The product was distributed globally and is labeled with “CareFusion, El Paso, TX.”

    March 23, 2021
    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination

    On December 28, 2020, the U.S. Food and Drug Administration announced that Sunstar Americas, Inc., expanded its October 27, 2020, voluntary recall of Paroex® chlorhexidine gluconate oral Rinse USP, 0.12%, because of possible contaminated with the bacteria Burkholderia lata.

    January 06, 2021
    FDA Warns Against Wearing Face Masks With Metal During MRI Exams
    U.S. Food and Drug Administration (FDA)

    FDA Warns Against Wearing Face Masks With Metal During MRI Exams

    The U.S. Food and Drug Administration (FDA) issued an alert on December 7, 2020, informing patients and healthcare providers that patients may be injured if they wear face masks with metal parts and coatings during magnetic resonance imaging (MRI) exams. Metal parts (e.g., nose pieces, nanoparticles, or antimicrobial coatings that may contain metal such as silver or copper) may become hot and burn patients during MRIs. 

    December 10, 2020
    Protect Patients With Cancer During Flu Season With Recommended Vaccinations
    Patient safety

    Protect Patients With Cancer During Flu Season With Recommended Vaccinations

    Patients with cancer are at increased risk for complications from the common flu. Plus, ensuring they receive recommended influenza vaccinations will reduce flu-related healthcare demands and decrease stress on the United States’ healthcare system, which is crucial as the nation approaches 10 million COVID-19 coronavirus cases. In response, the Centers for Disease Control and Prevention (CDC) isn’t waiting until National Influenza Vaccination Week, December 6–12, 2020, to promote vaccinations to high-risk populations.

    November 20, 2020
    Manage Malnutrition’s Monstrous Consequences in Patients With Cancer
    Treatment side effects

    Manage Malnutrition’s Monstrous Consequences in Patients With Cancer

    Nutritional status is one aspect of cancer care that may often be overlooked. Patients, particularly those with esophageal, gastric, pancreatic, and non-small cell lung cancers, have increased nutritional requirements because of their high resting energy expenditure. Treatment side effects further hinder a patient’s desire and ability to eat, creating a wider gap between energy intake and energy needs and placing patients with cancer at high risk for malnutrition.

    October 16, 2020
    Annual Survey Shows Youth Vaping Is Still National Epidemic
    Health Policy

    Annual Survey Shows Youth Vaping Is Still a National Epidemic

    In 2020, the number of middle and high school students who use e-cigarettes decreased by 1.8 million compared to 2019, the Centers for Disease Control and Prevention and U.S. Food and Drug Administration reported in the results of the 2020 National Youth Tobacco Survey. However, the results also showed that youth tobacco use is still an epidemic in the United States.

    September 21, 2020
    ONS Bridge

    Opioids Can Be Used Safely for Cancer-Related Pain

    During the current opioid epidemic, a safe, balanced approach to pain management is imperative. In an ONS Bridge presentation, Jeannine M. Brant, PhD, APRN, AOCN®, FAAN, discussed the use of opioids in patients with cancer.

    September 15, 2020
    ONS Bridge

    Black Box Warnings Guide Oncologic Emergencies in Acute Care and Outpatient Settings

    The transition of chemotherapy and immunotherapy delivery from the acute care and clinic settings to the home setting has created a need for innovative strategies to keep patients safe. Today, with decreased face-to-face interactions, the need for those strategies and tools is even greater in a system reliant on multiple facilities and disciplines to collaborate care in a time when resources are sometimes scarce or minimal, Mary Jo Sarver, ARNP, AOCN®, CRNI, VA-BC, LNC, said in an on-demand session for the inaugural ONS Bridge™ virtual conference.

    September 10, 2020
    The Case of the Major Malnutrition Concerns
    Oncology nurse education

    The Case of the Major Malnutrition Concerns

    Max, a 60-year-old patient with head and neck cancer, is receiving chemoradiation. Since his initial consult, he’s experienced a 12% weight loss from baseline, impaired swallowing, pain, anorexia, and dysgeusia. He has financial challenges, limited social support, poor health literacy, and a history of alcohol abuse. He has a feeding tube, but you suspect he is not using it. You reinforce prior education about malnutrition, and although Max refuses to be admitted to the hospital, he promises to do better.

    August 21, 2020
    How to Approach Medical Device Failures
    Oncology nurse education

    When Function Becomes Malfunction

    Malfunctioning medical products can pose safety risks to both patients and nurses and waste valuable time and resources. All medical devices and equipment used in the United States must pass specific manufacturing requirements before they can be approved for sale. But every product, regardless of performance, is subject to malfunction. A challenge for nurses is determining whether an issue is a rare failure or if the product is legitimately problematic.

    July 07, 2020
    Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment
    Cancer research

    Antibody-Drug Conjugates Join the Best of Two Worlds Into One New Treatment

    A new class of drugs, antibody-drug conjugates (ADCs), combines the specificity of targeted therapy with the cytotoxicity of chemotherapy for a powerhouse effect against certain types of cancer variants. Here’s what you need to know about this novel treatment modality.

    July 01, 2020
    Virtual Care for Patients With Cancer in New Jersey During COVID-19
    COVID-19

    Virtual Care for Patients With Cancer in New Jersey During COVID-19

    The COVID-19 coronavirus pandemic is unchartered territory with many unknowns, especially a new reality that nurses may be experiencing for the first time: virtual patient care. Even at a distance, the team at Jefferson Health New Jersey Sidney Kimmel Cancer Center in Sewell wanted to ensure we offered the same level of care and encouragement to patients in all phases of the cancer continuum, so here’s what we found worked for us.

    June 08, 2020
    • Current page 1
    • Page 2
    • Page 3
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲